A traditional plant extract protected aging hearts' mitochondria — in mice and lab-grown heart cells

Edited by Samael A. Tejada, Founder & Editor-in-Chief

Traditional remedies earn scientific standing one controlled experiment at a time. This one is unusually complete for its kind: an animal result, a cell result, and a blocker experiment that tests whether the proposed pathway is really doing the work.

What did the extract do in the aging-model mice?

D-galactose was used to induce aging-like changes in C57BL/6J mice. SGF administration significantly attenuated the resulting cardiac hypertrophy, ameliorated myocardial fibrosis and ROS overproduction, and preserved mitochondrial ultrastructure — the physical integrity of the heart's mitochondria under the microscope. Molecularly, SGF enhanced AMPK phosphorylation (a higher p-AMPKalpha/AMPK ratio) and upregulated two quality-control systems: the PGC-1alpha/NRF1/TFAM axis, which builds new mitochondria, and PINK1/Parkin signalling, which removes damaged ones (mitophagy). Protection plus both arms of mitochondrial quality control is a coherent pattern, not a single stray marker.

Why does the blocker experiment matter?

In H9c2 heart cells, SGF effectively suppressed D-galactose-induced senescence-like changes. When the researchers co-treated with Compound C, a pharmacological AMPK inhibitor, the beneficial effects were abolished — and SGF's action resembled that of AICAR, a known AMPK activator. That combination (benefit present, benefit removed by blocking the pathway, benefit mimicked by activating the pathway) is the standard preclinical logic for calling an effect AMPK-associated. The authors use exactly that measured language: the changes are consistent with an AMPK-associated pattern and may contribute to the cardioprotective effects via mitochondrial function.

What are the limits?

D-galactose aging is a model, not aging itself: it produces oxidative, aging-like injury on a compressed schedule, and compounds that rescue it do not automatically slow natural cardiac aging. SGF is a flavonoid mixture from a rhizome extract, so the active constituents, their doses in any human-usable preparation, and their bioavailability are all unresolved. There are no human studies of Smilax glabra flavonoids for cardiac or mitochondrial outcomes. File this as a well-constructed preclinical result that justifies further work — including, notably, a test in naturally aged animals — not as a reason to buy an extract.

Where the evidence stands

• Established: AMPK, the PGC-1alpha/NRF1/TFAM biogenesis axis and PINK1/Parkin mitophagy are established mitochondrial quality-control pathways in cardiac biology; D-galactose is a standard aging-like injury model.
• Preliminary: SGF's cardioprotection: one animal-plus-cell study (2026) with a pathway-blocker control supporting an AMPK-associated mechanism. No replication, no natural-aging model, no identified single active compound.
• Absent: Human evidence of any kind — no clinical trial, pharmacokinetic or safety data for Smilax glabra flavonoids on cardiac or mitochondrial outcomes.